You are here

Besnik Bajrami


Bajrami B, Kwak HJ, Loison F, Nombela AC, Mondal S, Sakai J, Silberstein L, Luo HR. G-CSF maintains controlled neutrophil mobilization during acute inflammation via negatively regulating CXCR2. J Exp Med 2016; 213 (10) :1999-2018.

Wellington S, Nag PP, Michalska K, Johnston SE, Jedrzejczak RP, Kaushik VK, Clatworthy AE, Siddiqi N, McCarren P, Bajrami B, Maltseva NI, Combs S, Fisher SL, Joachimiak A, Schreiber SL, Hung DT. A small molecule allosteric inhibitor of Mycobacterium tuberculosis tryptophan synthase. Nat Chem Biol. 2017 Sep;13(9):943-950. doi: 10.1038/nchembio.2420. Epub 2017 Jul 3.

Bajrami B*, Kwak HJ*, Jia Y, Mondal S, Roy S, Silberstein L, Luo HR. Myeloid-derived reactive oxygen species externally regulate emergency granulopoiesis, 2015, Immunity;42(1):159-71.

Besnik Bajrami, Ph.D.

Besnik Bajrami is a senior research scientist I in the Biochemistry Group of the Discovery Sciences Unit, within the Center for the Development of Therapeutics (CDoT) at the Broad Institute of MIT and Harvard under the direction of Virendar Kaushik. He leads a collaborative team interested in developing novel mass spectrometry (MS)-based biochemical, biophysical, and structural biology assays that are implemented across multiple therapeutic projects. His main research focus is to pioneer and advance methodologies that unravel difficult challenges in drug discovery with the goal of bringing transformative medicines to patients.

Bajrami’s main area of expertise is applying novel biochemical and biophysical MS techniques and peptide mapping, as well as native MS and hydrogen exchange-MS to study enzyme kinetics and compound affinity and to characterize drug targets and their interactions.

Prior to joining the Broad Institute in July 2015, Bajrami worked as a MS applications chemist at Waters, developing innovative bioanalytical liquid chromatography-mass spectrometry (LCMS)-based methodologies for ADME (absorption, distribution, metabolism, and excretion) and pharmacokinetic/pharmacodynamic studies. This experience was preceded by a postdoctoral fellowship at Harvard Medical School/Boston Children’s Hospital studying the role of neutrophils and hematopoietic stem cells in innate immunity and during inflammation.

Bajrami obtained his Ph.D. in chemistry from the University of Connecticut, concentrated on studying phase I (CYP450) and phase II metabolism and genotoxicity, during which time he was awarded the university’s Doctoral Dissertation Fellowship Award.

Contact Besnik Bajrami via email at

August 2019